Company Overview and News

 
HCOM / Hawaiian Telcom Holdco, Inc. 10-K (Annual Report)

2018-03-13 sec.gov
hcom_Current_Folio_10K Table of Contents <
Upvote Downvote

9
10 More Losers That Will Be Stocks to Buy in 2018 | InvestorPlace

2017-12-13 investorplace
2017 has been a great year for the broad markets – but not every stock has joined the fun. Retailers of all stripes, even with a recent rally, have struggled. Oil and gas plays have been choppy. Many healthcare stocks have been weak, with notable declines for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Celgene Corporation (NASDAQ:CELG), among others.
Upvote Downvote

 
BRIEF-Cincinnati Bell-Hawaiian Telcom Merger Receives Hawai'i DCCA Approval

2017-12-08 reuters
* HAWAIIAN TELCOM HOLDCO - HAWAI‘I DCCA APPROVAL OF TRANSFER OF CONTROL OF CO‘S CABLE FRANCHISE TO CINCINNATI BELL Source text for Eikon: Further company coverage:
Upvote Downvote

 
Hawaiian Telcom Holdco's (HCOM) CEO Scott Barber on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good day, ladies and gentlemen, and welcome to the Hawaiian Telcom Holdco, Inc., Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.
Upvote Downvote

 
HCOM / Hawaiian Telcom Holdco, Inc. 10-Q (Quarterly Report)

2017-11-08 sec.gov
hcom_Current folio_10Q Table of Contents &n
Upvote Downvote

 
HCOM / Hawaiian Telcom Holdco, Inc. 8-K (Current Report)

2017-11-07 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): November 7, 2017   Hawaiian Telcom Holdco, Inc. (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of incorporation)   001-34686 (Commission File Number)   16-1710376 (I.
Upvote Downvote

 
HCOM / Hawaiian Telcom Holdco, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-07 fintel.io
Hawaiian Telcom Holdco, Inc. (NASDAQ:HCOM) has 69 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 10,720,495 shares. Largest shareholders include Black Diamond Capital Management, L.l.c., Twin Haven Special Opportunities Fund Iii, L.p., Private Management Group Inc, Loomis Sayles & Co L P, and Wynnefield Capital Inc.
Upvote Downvote

 
HCOM / Hawaiian Telcom Holdco, Inc. / CINCINNATI BELL INC - AMENDMENT NO.1 TO SCHEDULE 13D (Activist Investment)

2017-11-07 sec.gov
Amendment No.1 to Schedule 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549          SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Hawaiian Telcom Holdco, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 420031106 (CUSIP Number) Christopher J. Wilson Cincinnati Bell Inc. 221 East Fourth Street Cincinnati, OH 45202 +1 513 397 9900 (Tel) With a copy to: Robert I.
Upvote Downvote

 
HCOM / Hawaiian Telcom Holdco, Inc. / CINCINNATI BELL INC - AMENDMENT NO.1 TO SCHEDULE 13D (Activist Investment)

2017-11-07 sec.gov
Amendment No.1 to Schedule 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549          SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Hawaiian Telcom Holdco, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 420031106 (CUSIP Number) Christopher J. Wilson Cincinnati Bell Inc. 221 East Fourth Street Cincinnati, OH 45202 +1 513 397 9900 (Tel) With a copy to: Robert I.
Upvote Downvote

 
Hawaiian Telcom Holdco 8-K (Prospectus)

2017-10-31 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): October 30, 2017   Hawaiian Telcom Holdco, Inc. (Exact Name of Registrant as Specified in Its Charter)   Delaware (State or Other Jurisdiction of Incorporation)   001-34686   16-1710376 (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
Hawaiian Telcom Holdco 8-K (Prospectus)

2017-10-31 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): October 30, 2017   Hawaiian Telcom Holdco, Inc. (Exact Name of Registrant as Specified in Its Charter)   Delaware (State or Other Jurisdiction of Incorporation)   001-34686   16-1710376 (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
Hawaiian Telcom Holdco 8-K (Current Report/Significant Event)

2017-10-31 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): October 30, 2017   Hawaiian Telcom Holdco, Inc. (Exact Name of Registrant as Specified in Its Charter)   Delaware (State or Other Jurisdiction of Incorporation)   001-34686   16-1710376 (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
Hawaiian Telcom Holdco DEFA14A

2017-10-31 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A (RULE 14a-101)   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )   Filed by the Registrant  x   Filed by a Party other than the Registrant  o   Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Solicitin
Upvote Downvote

 
Hawaiian Telcom Holdco DEFM14A

2017-10-05 sec.gov
DEFM14A Table of Contents   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934       Filed by the Registrant  ☒    Filed by a Party other than the Registrant  ☐ Check the appropriate box:      ☐    Preliminary Proxy Statement ☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒    Definitive Proxy Statement ☐    Definitive Additio
Upvote Downvote

 
Hawaiian Telcom Holdco 10-K (Annual Report)

2017-10-05 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS Item 8. Financial Statements and Supplementary Data Table of Contents   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one)     ý   ANNUAL REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 420031106